Presidio Pharmaceuticals, Inc. announced today that Nathaniel Brown, M.D., Chief Medical Officer, will present a late-breaker poster, “Safety and Pharmacokinetics of PPI-461, a Potent New Hepatitis C virus (HCV) NS5A Inhibitor with Pan-Genotype Activity” at the 61st AASLD meeting in Boston, MA, on November 1, 2010.
No Comments »
Filed under: Pharmacy News
Data presented today at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo.
No Comments »
Filed under: Pharmacy News
Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company’s novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne.
No Comments »
Filed under: Pharmacy News
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.
No Comments »
Filed under: Pharmacy News
Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.
No Comments »
Filed under: Pharmacy News
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the execution of a securities purchase agreement with a select group of institutional and accredited investors providing for a private placement, or PIPE financing.
No Comments »
Filed under: Pharmacy News
Oregon Health & Science University Doernbecher Children’s Hospital will lead the next phase of a landmark clinical trial to further assess the safety and preliminary effectiveness of purified human neural stem cells (HuCNS-SC-) as a potential treatment for infantile or late-infantile neuronal ceroid lipofuscinosis (NCL), a rare and currently fatal neurodegenerative disorder that affects infants [...]
No Comments »
Filed under: Pharmacy News
Data presented at a major medical meeting include findings that demonstrate improved handwriting performance in children with Attention Deficit Hyperactivity Disorder (ADHD) when taking CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) compared to placebo. This data, which was presented by McNeil Pediatrics™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc…
No Comments »
Filed under: Pharmacy News
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX™ orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France…
No Comments »
Filed under: Pharmacy News
AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect. NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA)…
No Comments »
Filed under: Pharmacy News
